<--GAT-->

FDA Approves Tecfidera for Treatment of Relapsing MS

by U.S. Medicine

May 6, 2013

WESTON, MA – The U.S. Food and Drug Administration has approved Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).

“No drug provides a cure for multiple sclerosis, so it is important to have a variety of treatment options available for patients,” said Russell Katz, MD, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “Multiple sclerosis can impair movement, sensation and thinking and have a profound impact on a person’s quality of life.”

Results from two clinical trials showed that those taking Tecfidera had fewer MS relapses compared with people taking an inactive pill (placebo). Tecfidera is made by Biogen Idec, Weston, MA.


Comments are closed here.


Related Articles

House Passes Bill to Create Education/Employment Arm of VA

WASHINGTON,—Legislators have reintroduced plans to create a fourth administration within the Department of Veterans Affairs—one dedicated to overseeing veterans’ education, transition and employment benefits. Currently these operations fall under the Veterans Benefits Administration, with VBA... View Article

Administrative Confusions Results in Little Oversight of VA’s Police Force

Suicides, Violence at VMACs Put Spotlight on Security WASHINGTON—As the number of suicides and other violent incidents at VA facilities grows, a spotlight is being thrown on VA’s internal police force and its ability to... View Article


U.S. Medicine Recommends


More From fda news

FDA News

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

FDA News

Long-Acting Insulins Approved by FDA

PLAINSBORO, NJ – Physicians treating diabetes patients have new weapons in their arsenal.The Food and Drug Administration recently approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve glucose control in... View Article

FDA News

FDA Approves Option for Schizophrenia, Bipolar Treatment

JERSEY CITY, NJ – A new option for treating schizophrenia and bipolar disorder in adults has been approved by the Food and Drug Administration.The drug Vraylar, cariprazine in capsule form, is manufactured by Forest Laboratories... View Article

FDA News

New DHA Screening Process Brings Drug Compounding Costs to 2% of April Levels

DHA Pharmacy Chief Says “Nefarious Actors” Targeted BeneficiariesBy Annette M. BoyleWASHINGTON — In April, the Defense Health Agency (DHA) spent $18 million a day in compound drug claims. By July, the daily costs had dropped... View Article

FDA News

Stivarga Approved for Some Stromal Tumors After Use of First-Line Therapies

WAYNE, NJ – Tthe U.S. Food and Drug Administration (FDA) has approved Bayer’s Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up